After many years of experience in the development of bioanalytical methods for small and large molecules, we have turned to smaller structures: miRNAs.
Micro-RNAs (miRNAs) are a variation of RNA that play an important role in the development of cancer. miRNAs are specifically detectable in blood and can thus be used for the diagnosis and prognosis of various tumor diseases. Such so-called “biomarker” studies can help to identify a specific course of disease and to tailor therapy to the individual patient. Furthermore, specific RNA drugs that can block miRNAs represent a new class of drugs that can revolutionize the treatment of cancer. However, the advantages of these two therapeutic approaches can only be exploited if suitable analytics are available that have been validated under GLP conditions.
Our two research projects result from this problem